Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02935777
Other study ID # POM-03
Secondary ID
Status Completed
Phase Phase 1
First received October 6, 2016
Last updated October 13, 2016
Start date April 2014
Est. completion date September 2014

Study information

Verified date October 2016
Source Queen Margaret University
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

The double-blinded, randomised, placebo-controlled crossover pilot study is conducted as a two week intervention after a pre-intervention registration and preparation period.

This study explores whether acute supplementation with pomegranate extract can modulate indicators of cognitive function and mood in healthy adults. Changes in physiological and biochemical markers are also investigated.


Description:

Participants are asked to visit the QMU clinical lab three times. The first visit is for general information, form completion, measurements and consent plus a practise session on COMPASS, the study computer software. Information and consent forms and a screening questionnaire are completed. Basic information such as age, sex, weight, height and blood pressure data are recorded. Lab visits 2 and 3, which are a week apart, constitute the intervention phase.

Participants are randomly assigned to either the pomegranate extract (PE) or placebo group.The researcher and participants are blinded to which capsules they are taking until data collection is complete. The randomisation process is carried out by independent technical staff who use an internet random number generator site to allocate treatment. The PE and placebo capsules look identical and are placed in sealed, labeled, pre-prepared opaque containers numbered by technicians.

At the next lab session (visit 2) participants begin their randomised study arm, taking either two pomegranate extract or two placebo capsules with water by mouth. Participants repeat the procedure at visit 3, where they crossover to the remaining intervention. Thus if participant A consumed placebo capsules at visit 2, the participant would take pomegranate extract capsules at visit 3, following a washout period of a week. If participant B consumed pomegranate extract on visit 2, the participant would then take the placebo capsules at visit 3.

At each visit, participants complete two computer testing sessions lasting approximately 45 minutes - one pre and one post capsule ingestion. After the capsule is taken there is a one hour absorption period before the next computer test session begins.

Participants are fasted from tea and coffee overnight and abstain for the period of the intervention in the morning. On the day before the tests, they are requested to refrain from alcohol, recreational drugs, and vigorous exercise.

Participants are also required to restrict herbal extracts, food supplements and polyphenols such as dark chocolate, fruit rich in polyphenols and antioxidants to less than three portions for 24 hrs beforehand. A 24 hour pre test food diary is completed to assist in compliance. Participants are also advised to have a good night's sleep - at least 6−8 h during the night before the study day - and should not be more stressed than usual. These aspects are confirmed before participants are allowed to commence their sessions.

Pre-study saliva collection is completed at home by participants early in the morning. This provides a biochemical marker which aims to support both cognitive findings and the results from the Bond Lader mood questionnaire completed during the computer testing. Instructions are given to participants for saliva collection and the samples analysed for cortisol and cortisone. Participants are instructed to have their usual breakfast except for coffee or tea. Blood pressure is taken pre and post study on visits 2 and 3.

The baseline computerised cognitive test battery is administered in the clinic at 9am lasting around 45 mins. The investigator then observes the participants consuming their scheduled capsules. After a one hour quiet absorption period around 11am, blood pressure is taken again. The post cognitive testing battery is completed once more and then a second post study saliva collection is taken. Participants complete the intervention around 12 noon. All assessments are carried out on a QMU computer, with the same laptop used by each participant at baseline and post intervention assessments.

The cognitive testing is conducted under controlled laboratory conditions with the assessments at baseline and post study always performed at the same time of day (between 0830 and 1200) for each participant.

Participant responses to the cognitive tests are recorded automatically by the computer software during the testing battery at visits 2 and 3.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date September 2014
Est. primary completion date July 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Healthy

- Aged 18-65

- Enjoy computer tasks

Exclusion Criteria:

- Diagnosis with any neurological, psychiatric or significant medical condition which could affect cognitive function

- Known cognitive impairment

- Use of any prescription, herbal or recreational drugs

- Gastrointestinal disease

- Pregnancy or breastfeeding

- Pomegranate allergy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Pomegranate Extract
The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
Placebo capsule
One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.

Locations

Country Name City State
United Kingdom Queen Margaret University Edinburgh Scotland

Sponsors (2)

Lead Sponsor Collaborator
Angela Stockton Northumbria University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Simple reaction time (attention and vigilance, speed of attention) Reaction time in msec. 1-2 hours No
Primary Choice reaction time (attention and vigilance, speed and accuracy of attention) Arrows pointing left and right will appear on the screen at irregular intervals. The participant is required to indicate the direction of the arrow as quickly as possible, whenever an arrow is displayed. Measured by % accuracy, overall correct responses and reaction time (ms). 1-2 hours No
Primary Bond Lader mood scales Mood is measured via the Bond Lader series of mood scales, each scored out of 100. From these scales three composite scores are calculated describing feelings of 'Alert', 'Calm' and 'Content', also presented as a score out of 100. 1-2 hours No
Primary Digit vigilance (attention and vigilance, speed and accuracy of attention) A fixed number will appear on the right of the screen and a series of changing numbers will appear on the left side of the screen. Participants are required to make a response when the number on the left matches the number on the right. Measured by reaction time (ms) and %accuracy of responses. 1-2 hours No
Primary Word presentation (secondary memory) then delayed Word recall (quality of memory) A list of words is displayed on the screen, one word at a time. Participants are given 60 seconds to write down as many of the words they were shown earlier as they can. This task was performed following following a delay between the presentation and recall (delayed recall). no of correct responses and % accuracy. 1-2 hours No
Primary Word recognition (secondary memory, quality and speed of memory) All target words that were shown during Word Presentation plus an equal number of decoys will be displayed on the screen one at a time. Participants indicate if they remember seeing the word earlier or not. measured by correct no of responses, errors and reaction time (ms). 1-2 hours No
Primary Rapid Visual Information Processing (RVIP) (cognitive demand) A series of numbers are displayed individually on the screen in quick succession (at a rate of 100 numbers per minute) and participants are required to respond when they see 3 odd numbers in a row or three even numbers in a row. Measured by % accuracy, no of false alarms and reaction time (ms). 1-2 hours No
Primary Picture presentation (secondary memory) and delayed recognition(secondary memory, speed and quality of memory) A series of pictures are displayed on the screen, one at a time. After a delay, all target pictures shown during Picture Presentation plus an equal number of decoys will be displayed on the screen one at a time. For each stimulus participants select 'Yes' or 'No' to indicate if they have seen the picture before or not. The task is measured by reaction time (ms), % accuracy and no of correct responses. 1-2 hours No
Primary Corsi blocks lite (working memory, spatial memory) Blue squares on a black background are displayed on the screen. Some of them change to red and back to blue again in a sequence. Participants are required to remember this sequence. The task is repeated five times at each level of difficulty with the sequence span increasing from 4 upwards, until the participant can no longer correctly recall the sequences. The task continues up to 6 squares in each sequence, while participants make enough correct responses. As soon as they make less than 3 correct responses (out of the five in one level) the task will end. All participants complete levels 4-6 regardless of incorrect responses. Results are measured by a span score: This score is calculated as the average of the last 3 correctly completed trials. For example, if the participant correctly responds to all five Level 4 trials and only one Level 5 trial, their span score would be 4.3 [(4 + 4 + 5)/3]. 1-2 hours No
Secondary Pre and post blood pressure changes Measurement of systolic and diastolic blood pressure in mmHg. 1-2 hours No
Secondary Pre-post cortisol and cortisone changes Collection of saliva which is processed via ELISA to measure cortisol and cortisone in ng/mL 3-4 hours No
See also
  Status Clinical Trial Phase
Recruiting NCT05322343 - Biobank and Brain Health in Bordeaux.
Completed NCT01632813 - Leuven Growing Into Deficit Follow-up Study N/A
Active, not recruiting NCT06309914 - The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States N/A
Active, not recruiting NCT03030053 - The Effects of Flavonoid Supplementation on Cognition and Neural Mechanisms in Healthy Older Adults N/A